Telmisartan Should Be Continued in Patients with Urothelial Carcinoma
There is no evidence-based contraindication to continuing telmisartan in patients with urothelial carcinoma, and it should be maintained for its cardiovascular and renal protective benefits unless standard contraindications apply.
Evidence Base
The FDA label for telmisartan lists only three absolute contraindications: known hypersensitivity/angioedema to telmisartan, co-administration with aliskiren in diabetic patients, and pregnancy 1. Notably, cancer—including urothelial carcinoma—is not listed as a contraindication or precaution.
The concern about ARBs and cancer risk has been thoroughly investigated. A large observational study of 62,109 ARB users specifically examined telmisartan's cancer risk and found no association between telmisartan use and increased cancer incidence (adjusted HR: 0.93,95% CI: 0.81-1.06) 2. This included analysis of specific cancer sites relevant to urology: bladder cancer was not separately reported, but colorectal cancer showed no significant association (HR: 1.41,95% CI: 0.95-2.10), and the study concluded that telmisartan provides "reassurance as to the short-term safety" regarding cancer risk 2.
Clinical Decision Framework
Continue Telmisartan If:
- Patient has established cardiovascular indications (hypertension, cardiovascular risk reduction) 1
- Renal function is adequate for monitoring (particularly important in urothelial cancer patients who may undergo nephroureterectomy)
- No standard contraindications exist
Monitor Closely For:
- Renal function deterioration: Patients with urothelial carcinoma may have compromised renal function from tumor obstruction, prior chemotherapy, or surgical intervention. Check serum creatinine and electrolytes every 3-6 months 1
- Hyperkalemia: Particularly in patients with advanced renal impairment or those receiving cisplatin-based chemotherapy. Obtain periodic serum electrolytes 1
- Hypotension: Especially if patient is volume-depleted from chemotherapy-induced nausea/vomiting or reduced oral intake 1
Specific Considerations in Urothelial Cancer Context:
For patients undergoing nephroureterectomy: Telmisartan's renal protective effects may be particularly valuable in preserving function of the remaining kidney. Studies demonstrate telmisartan safely reduces proteinuria and blood pressure even in patients with chronic kidney disease and serum creatinine up to 4.0 mg/dL 3, 4.
For patients receiving systemic therapy: The comprehensive NCCN and EAU guidelines for bladder cancer management 5, 6, 7 make no mention of discontinuing ARBs during chemotherapy, immunotherapy, or antibody-drug conjugate treatment. Recent evidence shows that immune checkpoint inhibitors can cause immune-related adverse events that may affect renal function 8, making blood pressure control and renal monitoring even more critical—not a reason to discontinue telmisartan.
For patients with borderline renal function: If GFR is marginal for cisplatin eligibility (a key consideration in muscle-invasive bladder cancer), telmisartan should be continued with close monitoring rather than discontinued, as its renal protective effects may help preserve remaining function 3.
Common Pitfalls to Avoid
- Do not reflexively discontinue telmisartan upon cancer diagnosis: There is no evidence supporting this practice
- Do not confuse cancer-related renal dysfunction with telmisartan-induced changes: Urothelial cancer itself causes obstructive uropathy and renal impairment; distinguish this from medication effects
- Do not substitute carboplatin for cisplatin solely due to telmisartan use: Cisplatin eligibility should be based on actual measured GFR, not theoretical concerns about ARB use 9
The FDA label explicitly states telmisartan can be used in patients with renal impairment including those on hemodialysis, though blood pressure should be monitored for orthostatic hypotension 1. This reinforces that renal considerations are about monitoring, not discontinuation.